Please login to the form below

Not currently logged in
Email:
Password:

Insulin prices

This page shows the latest Insulin prices news and features for those working in and with pharma, biotech and healthcare.

Lilly joins new Medicare scheme to reduce insulin prices

Lilly joins new Medicare scheme to reduce insulin prices

Lilly has faced particularly strong criticism, after its widely-used Humalog insulin rose from $34 to $234 per vial between 2001 and 2015. ... excludes biologics such as insulin as well as intravenous drugs and controlled substances.

Latest news

  • New drugs drive Novo Nordisk despite insulin price pressures New drugs drive Novo Nordisk despite insulin price pressures

    Although sales of its newer drugs have been growing, Novo has been facing challenges to its insulin franchise – in particular in the US, where prices of these products have been heavily ... Along with other insulin manufacturers, including Sanofi and

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    Sales of long-acting insulin also decreased by 2%, which was driven by declining Levemir sales. ... Insulin prices have been a hotly-debated topic as pharma companies face pricing pressure from patient groups and government officials, particularly in the

  • Democrats’ final pricing plan announced, 250 drugs targeted Democrats’ final pricing plan announced, 250 drugs targeted

    Pharma companies, under the proposed plan, would also have to offer agreed prices to private health insurance companies. ... Drug pricing in the US has been under scrutiny, with drugs prices, including insulin, increasing exponentially.

  • Novo follows Sanofi, Lilly with insulin price cut in US Novo follows Sanofi, Lilly with insulin price cut in US

    which offered a 50% cheaper version of its Humalog (insulin lispro) the following month. ... Those plans push list prices to patients to fulfil a deductible, which sometimes means paying thousands of dollars.”.

  • Novo Nordisk shareholder revolt reaches Europe Novo Nordisk shareholder revolt reaches Europe

    The US class action suit claims that Novo Nordisk and other insulin manufacturers entered into “an improper, collusive agreement to increase the prices of their insulin drugs, as evidenced by synchronised, ... skyrocketing prices for the insulin

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • The fight for affordable insulin The fight for affordable insulin

    Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma. ... prices. Reliance on US revenues. For the big three insulin companies, their reliance on US revenues runs deep.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics